QNTM

Quantum BioPharma Ltd.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$21.24M
P/E Ratio
EPS
$-7.48
Beta
0.44
52W High
$31.91
52W Low
$2.07
50-Day MA
$5.02
200-Day MA
$7.19
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. (QNTM) is a pioneering biotechnology firm dedicated to the development of breakthrough therapies for oncology and autoimmune conditions. The company boasts a promising pipeline of biopharmaceutical products, underscored by its commitment to cutting-edge research and innovation. Through strategic partnerships and an accomplished leadership team, Quantum is well-equipped to navigate the evolving biopharmaceutical landscape, addressing significant unmet medical needs. As the demand for novel therapeutics continues to grow, QNTM offers a compelling investment opportunity for institutional investors looking to tap into this high-growth sector.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-14.33M
Operating Margin0.00%
Return on Equity-2057.00%
Return on Assets-62.40%
Revenue/Share (TTM)$0.00
Book Value$0.10
Price-to-Book38.16
Price-to-Sales (TTM)91.86
EV/Revenue98.56
EV/EBITDA-1.57
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$6.40M
Float$5.96M
% Insiders12.36%
% Institutions9.86%

Historical Volatility

HV 10-Day
50.97%
HV 20-Day
61.44%
HV 30-Day
121.15%
HV 60-Day
139.14%
HV Rank

Volatility is currently contracting

Latest News

Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

GlobeNewsWire7/7/2026Neutral
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

GlobeNewsWire6/25/2026Neutral
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

GlobeNewsWire6/23/2026Neutral
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Disseminated on behalf of  Quantum BioPharma , may include paid advertisements. AUSTIN, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

GlobeNewsWire6/2/2026Neutral
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to announce that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC (the “Agency”) beginning on June 8, 2026.

GlobeNewsWire6/2/2026Neutral
Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

GlobeNewsWire6/1/2026Neutral
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results.

GlobeNewsWire5/18/2026Neutral
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzd™, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commercialization strategy. With the functional beverage market projected to reach $198 billion in 2026 and expected to grow at a 10.79% CAGR, Mr. Buzbuzian brings the vision and capital markets acumen required to capitalize on this unprecedented market opportunity. His mandate includes executing a nationwide rollout beginning with strategic market expansion into South Florida and Texas — two of America's most dynamic consumer markets, as well as listing the Company on a stock exchange.

GlobeNewsWire4/22/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026